Save

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

PHASE3RECRUITING

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Simpliy with AI

Study details:

This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy versus Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Histologically or cytologically documented non-squamous NSCLC.

Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.

Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved targeted first-line therapies.

Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.

Known tumour PD-L1 expression status defined as TC ≥ 50%

At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline

ECOG performance status of 0 or 1

Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention

Exclusion criteria

Prior systemic therapy for advanced/metastatic NSCLC.

Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.

History of another primary malignancy within 3 years

Active or prior documented autoimmune or inflammatory disorders (with exceptions)

Any evidence of severe or uncontrolled systemic diseases, including, but not limited to active bleeding diseases, active infection, active ILD/pneumonitis, cardiac disease.

Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.

History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening

Has severe pulmonary function compromise resulting from intercurrent pulmonary illnesses

Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.

History of leptomeningeal carcinomatosis

Known clinically significant corneal disease

Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled

History of active primary immunodeficiency

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2024-04-11

Primary completion: 2028-04-27

Study completion finish: 2030-05-24

Study type

TREATMENT

Phase

PHASE3

Trial ID

NCT06357533

Intervention or treatment

DRUG: Datopotamab Deruxtecan

DRUG: Rilvegostomig

DRUG: Pembrolizumab

Conditions

• Non-Small Cell Lung Cancer

Image related to Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
DRUG: Datopotamab Deruxtecan and other drugs
Clayton, Not Specified, Australia and more
Sponsor: AstraZeneca

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Research Site

Research sites nearby

Select from list below to view details:

Research Site
Clayton, Not Specified, Australia
Research Site
Melbourne, Not Specified, Australia
Research Site
South Brisbane, Not Specified, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Arm 1: Dato-DXd in Combination With Rilvegostomig Participants in the Dato-DXd in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.	DRUG: Datopotamab Deruxtecan Datopotamab Deruxtecan IV (intravenous)
EXPERIMENTAL: Arm 2: Rilvegostomig Monotherapy Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.	DRUG: Rilvegostomig Rilvegostomig IV (intravenous)
ACTIVE_COMPARATOR: Arm 3: Pembrolizumab Monotherapy Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.	DRUG: Pembrolizumab Pembrolizumab IV (intravenous)

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Progression-Free Survival (PFS) in TROP2 biomarker positive participants.	PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis.	Approximately 4 years
Overall Survival (OS) in TROP2 biomarker positive participants.	OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of OS.	Approximately 6 years

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Progression-Free Survival (PFS) in the intent-to-treat (ITT) population.	PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • ITT population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis.	Approximately 4 years
Overall Survival (OS) in the intent-to-treat (ITT) population.	OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • ITT population The measure of interest is the HR of OS.	Approximately 6 years
Objective Response Rate (ORR)	ORR is defined as the proportion of participants who have a CR or PR, as determined by BICR per RECIST 1.1. The analyses will include all randomised participants, as randomised, with measurable disease at baseline, in the following populations: * TROP2 biomarker positive population * ITT population Data obtained from randomisation up until progression, or the last evaluable assessment in the absence of progression, will be included in the assessment of ORR, regardless of whether the participant withdraws from therapy. Participants who go off treatment without a response or progression, receive a subsequent therapy, and then respond will not be included as responders in the ORR. The measure of interest is the OR of the ORR. ORR by investigator will be reported as a sensitivity analysis.	Approximately 4 years
Duration of Response (DoR)	DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR and investigator assessment or death due to any cause. The analyses will include all randomised participants who have a response, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following populations: * TROP2 biomarker positive population * ITT population The measure of interest is the median of DoR. DoR by investigator will be reported as a sensitivity analysis.	Approximately 4 years
Participant-reported lung cancer symptoms of NSCLC in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab.	Time to deterioration in pulmonary symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ. Time to deterioration in overall lung cancer symptoms as measured by the NSCLC-SAQ. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations: * TROP2 biomarker positive population * ITT population The measure of interest is the HR of time to deterioration in pulmonary symptoms and the HR of time to deterioration in overall lung cancer symptoms.	Approximately 6 years
Participant-reported physical functioning in participants treated with Dato DXd in combination with rilvegostomig relative to pembrolizumab.	Time to deterioration in physical functioning as measured by PROMIS Physical Function short form 8c. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations: * TROP2 biomarker positive population * ITT population The measure of interest is the HR of time to deterioration in physical functioning.	Approximately 6 years
Participant-reported GHS/QoL in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab.	Time to deterioration in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172. Time to deterioration is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analysis will include all randomised participants, in the following populations: * TROP2 biomarker positive population * ITT population The measure of interest is the HR of time to deterioration in GHS/QoL.	Approximately 6 years
Pharmacokinetics (PK)	Concentration of rilvegostomig, Dato-DXd, total anti TROP2 antibody, and MAAA 1181a (payload deruxtecan) in plasma or serum and PK parameters (peak and trough concentrations).	Approximately 6 years
Immunogenicity	Presence of ADA for Dato-DXd and rilvegostomig (confirmatory results, titres and neutralising antibodies for confirmed positive samples).	Approximately 6 years
Second Progression-Free Survival (PFS2).	PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death. Progression event includes radiological (RECIST 1.1) or clinical disease progression. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard practice. The analyses will include all randomised participants, as randomised, regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits, in the following populations: * TROP2 biomarker positive population * ITT population The measure of interest is the HR of PFS2.	Approximately 6 years

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations